Transcription of Federal Response to COVID-19: Therapeutics Clinical ...
{{id}} {{{paragraph}}}
Federal Response to COVID-19: Therapeutics Clinical Implementation Guide Outpatient administration guide for healthcare providers 12/29/2021. 1 Introduction to COVID-19 Outpatient Therapeutics &. Product Selection 2 Overview of Emergency Use Authorizations 3 Overview of Outpatient Therapeutic Distribution Process 4 Monoclonal Antibody Administration Table of Site and patient logistics Patient Pathways to Monoclonal Administration Team Roles and Responsibilities Contents Indications and Administration Response to Adverse Events Supplies and Resources 5 Oral Antiviral Administration Introduction to COVID-19 Oral Antiviral Therapies Prescriber Journey for Prescribing Pharmacy Journey for Dispensing Patient Journey 6 Additional Resources 2. 1. Introduction to COVID-19. Outpatient Therapeutics & Product Selection Summary of COVID-19 Preventative Agents & Therapeutics Exposed Mild to Moderate No Illness Hospital Admission ICU Admission Per CDC Close Contact Criteria Symptoms Hospitalized, Hospitalized, Hosp.
Feb 15, 2022 · Paxlovid™ is not authorized for pre-exposure or post -exposure prophylaxis for prevention of COVID-19 Not authorized for use longer than 5 consecutive days Paxlovid™ may only be prescribed for an individual patient by physicians, advanced practice registered
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document:
{{id}} {{{paragraph}}}